News

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

by

ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted … Read more

Comprehensive Access to 600+ Available Deals and Contract Documents

by

DUBLIN, June 2, 2023 /PRNewswire/ — The “Global Musculoskeletal Partnering 2016-2023: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering. This report provides the full collection of musculoskeletal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016. Trends in musculoskeletal partnering deals Financial deal terms for headline, upfront and royalty … Read more

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

by

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months (median study follow-up time of 12.4 months) Biliary tract cancers (BTC) are an … Read more

Asep Inc. Announces Ground-breaking A.I. Technology for Rapid Identification of Severe Sepsis and Improved Superbug Therapies

by

VANCOUVER, BC, June 2, 2023 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) announces the ground-breaking use of artificial intelligence (AI) to rapidly identify infections at increased risk of severe sepsis. The method was developed by the Hancock Lab, under the guidance of Dr. Robert E.W. … Read more

Liminal BioSciences gibt F&E-Update bekannt (Liminal BioSciences Provides)

by

Nominierung von LMNL6326 als führender präklinischer Kandidat für das OXER1-Antagonisten-Entwicklungsprogramm zur Behandlung eosinophil bedingter Erkrankungen  Fortschritte bei der Beantragung einer klinischen Studie (CTA), die präklinische Studien mit LMNL6511 ermöglicht, um den CTA-Antrag für eine klinische Phase-1-Studie in H2 2023 zu unterstützen  Gewinnung vonErkenntnissen aus präklinischen in-vivo -Studien mit LMNL6511 zur weiteren Verfeinerung des Spektrums möglicher … Read more

At ASCO ’23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics

by

CHICAGO, June 2, 2023 /PRNewswire/ — ASCO 2023 – McCormick Place, In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st, Perthera, the leader in AI precision oncology solutions, introduced its latest generation of clinical support tools, including Perthera Lab Direct and Perthera RWE Navigator. … Read more

Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Young Investigator Awards

by

— Patricia Mae Garcia Santos, MD, MS, receives annual Conquer Cancer-Women Leaders in Oncology “Women Who Conquer Cancer” Young Investigator Award — — Tafadzwa L. Chaunzwa, MD, MHS, receives annual Conquer Cancer-Vaniam Group LLC Young Investigator Award, dedicated to Black, African, or African American cancer researchers — CHICAGO, June 2, 2023 /PRNewswire/ — Conquer Cancer®, … Read more

MEDSIR’s PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer

by

MEDSIR PHERGain trial is the first to use an adaptive design in HER2-positive early breast cancer.  Tweet this PHERGain is a randomized, controlled phase 2 clinical trial that involved 356 early-stage HER2-positive breast cancer patients from 45 centers in seven European countries. It was sponsored by MEDSIR, a company dedicated to advancing clinical research in … Read more

Global Genomics Market Analysis Report 2023: An $83.1 Billion Market by 2028 from $46.2 Billion in 2023

by

DUBLIN, June 2, 2023 /PRNewswire/ — The “Genomics Market by Product & Service (Consumables, Instrument, System & Software), Technology (Sequencing, PCR, Microarray), Study Type (Epigenomics, Biomarker Discovery), Application (Drug Discovery, Diagnostic, Agriculture) – Global Forecast to 2028” report has been added to  ResearchAndMarkets.com’s offering. The global genomics market is projected to reach USD 83.1 billion … Read more

EpicentRx Presents Updates on its Oncology Clinical Development Programs at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

by

Company details follow-on Phase 2b study design in head and neck cancer for its lead small molecule candidate, RRx-001 Company also presented positive first-in-human data from its TGF-β trap vector, AdAPT-001 TORREY PINES, Calif., June 2, 2023 /PRNewswire/ — EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company, today presented clinical progress updates for two lead … Read more